<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392312</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-MA-ACN001</org_study_id>
    <nct_id>NCT02392312</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients</brief_title>
  <official_title>Safety and Efficacy of Individual Batches of ATG-F in Kidney Transplant Recipients: Multicentre, Prospective, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma China, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, prospective, observational study to evaluate the safety and efficacy of
      individual batches of ATG-F in kidney transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2015</start_date>
  <completion_date type="Actual">March 16, 2018</completion_date>
  <primary_completion_date type="Actual">March 16, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse event</measure>
    <time_frame>up to 3 months post-transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical diagnosis of acute rejection</measure>
    <time_frame>up to 3 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function: serum creatinine</measure>
    <time_frame>at month 1 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of delayed graft function (DGF)</measure>
    <time_frame>up to 3 months post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>up to 3 months post-transplantation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">950</enrollment>
  <condition>Kidney Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>ATF-Fresenius S</arm_group_label>
    <description>intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATF-Fresenius S</intervention_name>
    <description>intravenous</description>
    <arm_group_label>ATF-Fresenius S</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Governmental Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ATG-F administration to prophylaxis rejection in kidney transplantation recipient.

          -  Patients capable to understand the purposes and risks of the study, who are willing
             and able to participate in the study and from whom written and dated informed consent
             to participate in the study is obtained.

        Exclusion Criteria:

          -  Hypersensitivity to the active substance or to any of the excipients.).

          -  Subjects with bacterial, viral, mycotic or parasitic infections, which are not under
             adequate therapeutic control.

          -  Solid organ transplant subjects with severe thrombocytopenia, i.e. less than 50,000
             platelets/Âµl because ATG-F may enhance thrombocytopenia and thus increase the risk of
             hemorrhage.

          -  Current malignancy or a history of malignancy (within the past 5 years), except
             non-metastatic basal or squamous cell carcinoma of the skin or carcinoma in-situ of
             the cervix that has been treated successfully.

          -  Subject is receiving a Human Leukocyte Antibody (HLA) identical living donor organ.

          -  Subject is unlikely to comply with the visits scheduled in the protocol in the opinion
             of investigator or has a history of non-compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma China, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site: CN00004</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00011</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00012</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00013</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00016</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00002</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00003</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00018</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00023</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00021</name>
      <address>
        <city>Haikou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00022</name>
      <address>
        <city>Haikou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00019</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00020</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00006</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00017</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00028</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00030</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00015</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00010</name>
      <address>
        <city>Shiyan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00014</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00005</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00031</name>
      <address>
        <city>Wulumuqi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00001</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00033</name>
      <address>
        <city>Yantai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CN00007</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney transplant</keyword>
  <keyword>ATG-F</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

